Improving the Prognosis for Patients with BRAF-Mutant and/or MSI-H mCRC
| Overview / Abstract: |
Are you current with the latest updates with MSI-H/dMMR and/or BRAF-mutant metastatic colorectal cancer? In this case-based activity, leading expert and researcher, Dr. Dung Le discusses the latest approvals and recommendations for patients with MSI-H/dMMR and/or BRAF-mutant mCRC. This activity also features interactive case presentations which involve biomarker testing, treatment selection, and mitigating potential adverse events. |
|
Expiration |
Oct 25, 2022 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
|
Format |
Webinar / Webcast / Video |
|
Credits / Hours |
.75 |
|
Accreditation |
ACCME |
|
Is This Activity Certified for "Live" Credit? |
YES |
|
Presenters / Authors / Faculty |
Dung Le, MD |
|
Sponsors / Supporters / Grant Providers |
Sponsored by the Academy for Continued Healthcare Learning (ACHL). This activity is supported through an Independent Medical Education grant from Merck & Co., Inc.. |
|
Keywords / Search Terms |
ACHL CME, CE, Continuing Medical Education, CME/CE, Online Learning, Case Study, Case-based CME activity, oncology, gastroenterology, metastatic colorectal cancer, biomarker testing for mCRC, BRAF-mutant, MSI-H CRC, treatment, BRAF gene, protein kinase, Dr. Dung Le, BEACON, CRC, colorectal cancer, immunotherapy, immune checkpoint inhibitors, KEYNOTE-177, CheckMate142, pembrolizumab, nivolumab Free CE CME Live CE CME |
|